SecBot SecBot

ARDX

ARDELYX, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001437402 Biotech & Drug Discovery
$3.03 +0.03 (+1.00%)
Oct 27 4:00 PM ET · prev $3.00
Market cap
$797.4M
Small cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$13.50
+346% · range $8.00–18.00
Next earnings
Nov 3
in 7 days · EPS est. −$0.02
1 year
−40.6%
from $5.10 · Oct 27
30 days
−11.1%
from $3.41
52-week range
$3.00–7.99
−62% from high · low Oct 26
Avg volume 20D
4.32M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$1.6M
0 buyers · 8 sellers · since May 21
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
13
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/7 ·Next Earnings date, Nov 3, 2026
Strongest NEUTRAL Ardelyx announced three abstracts will be presented at ASN Kidney Week 2026, highlighting real-world…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    8 insiders sold $1.6M.

  • InstitutionsMIXED

    Q2 2026: 15 added (0 new), 14 trimmed or exited.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.043 → −$0.015 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    13% below its 50-day average. New closing low $3.00 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
Rubric Capital Management LPDOUBLED16,202,700$82.6M
MORGAN STANLEYADD2,389,546$12.2M
SCHRODER INVESTMENT MANAGEMENT GROUPDOUBLED1,161,238$6.1M
CITADEL ADVISORS LLCTRIM1,030,174$5.3M
SUSQUEHANNA INTERNATIONAL GROUP, LLPADD916,037$4.7M
RENAISSANCE TECHNOLOGIES LLCTRIM892,593$4.6M
CITIGROUP INCDOUBLED311,021$1.6M
WELLS FARGO & COMPANY/MNADD280,470$1.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy9Buy7Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +346%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 19, 2026Wedbush
REITERATE
REITERATEOutperform
Aug 18, 2026Wedbush
REITERATE
REITERATEOutperform
Aug 17, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Aug 10, 2026Citigroup
MAINTAIN
MAINTAINBuy
Aug 7, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Aug 7, 2026BTIG
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.6M
sold · 8 insiders
DateInsiderTypeValue
Aug 21, 2026
RAAB MICHAEL
President & CEO
SELL$57.9K
Aug 21, 2026
RAAB MICHAEL
President & CEO
SELL$74.0K
Aug 21, 2026
Williams Laura A
Chief Patient Officer
SELL$13.4K
Aug 21, 2026
Williams Laura A
Chief Patient Officer
SELL$11.9K
Aug 21, 2026
Williams Laura A
Chief Patient Officer
SELL$9.4K
Aug 21, 2026
RAAB MICHAEL
President & CEO
SELL$32.4K
Aug 21, 2026
RAAB MICHAEL
President & CEO
SELL$61.6K
Aug 21, 2026
Williams Laura A
Chief Patient Officer
SELL$6.7K

Earnings setup

Estimates
Nov 3
reports in 7 days
−$0.02
EPS estimate, this quarter
−135%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.02-$0.06–$0.02-9.1%$128.7M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Ended · Capitol Q3 2026 · filed Oct 20
Lobbying Q3 $520K +4.0% QoQ
YoY −20.0% vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
HCRHealth IssuesMMMMedicare/MedicaidPHAPharmacy
BillH.R. 6214
8 quarters Open in Washington ›

Corporate Lobbying

This company's lobbying spend, firms, issues and congressional activity are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Other
🔒 Fresh data, subscribers only
Oct 5, 2026 Press
Ardelyx announced three abstracts will be presented at ASN Kidney Week 2026, highlighting real-world evidence for…
Impact 2/10
Aug 25, 2026 SEC
Seven ARDX insiders, including the CEO and CFO, sold a total of $229K in open-market sales on August 21, 2026, all at…
CLUSTER — Impact 2/10
Aug 25, 2026 SEC
Six ARDX insiders, including CEO Michael Raab and the Chief Commercial Officer, collectively sold $226K in open-market…
CLUSTER — Impact 2/10
Aug 21, 2026 SEC
CEO Michael Raab filed a Form 144 notice to sell 44,500 shares (~$179K at filing) on August 21, 2026, following a…
144 — Impact 2/10
Aug 21, 2026 Insider
RAAB MICHAEL sold 15,009 shares
President & CEO @ $3.86 ($57.9K)
Aug 21, 2026 Insider
RAAB MICHAEL sold 19,178 shares
President & CEO @ $3.86 ($74.0K)
Aug 21, 2026 Insider
Williams Laura A sold 3,486 shares
Chief Patient Officer @ $3.86 ($13.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
ARDX Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Oct 23, 2026
Press release
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data...
Oct 22, 2026
Trial readout
Results Pending: Tenapanor 50 MG (Phase 3) — Completed 64d ago
Trial: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years Sponsor: Ardelyx…
Oct 20, 2026
Press release
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX
NEW YORK, Oct. 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the…
Oct 19, 2026
Press release
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of…

SecBot reports

13 filings · 3 press releases · 1 bullish · 0 bearish · 12 neutral
All ARDX filing & press-release reports (16)